RVMD

RVMD

USD

Revolution Medicines Inc. Common Stock

$58.570+0.580 (1.000%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$57.990

高値

$59.680

安値

$57.740

出来高

2.37M

企業ファンダメンタルズ

時価総額

10.9B

業種

バイオテクノロジー

United States

取引統計

平均出来高

2.19M

取引所

NMS

通貨

USD

52週レンジ

安値 $29.17現在値 $58.570高値 $62.4

関連ニュース

Analyst Upgrades

RBC Capital Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $77

RBC Capital analyst Leonid Timashev initiates coverage on Revolution Medicines with a Outperform rating and announces Price Target of $77.

もっと見る
RBC Capital Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $77
GlobeNewswire

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today

もっと見る
Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
GlobeNewswire

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today

もっと見る
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
Analyst Upgrades

Mizuho Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $90

Mizuho analyst Joseph Catanzaro initiates coverage on Revolution Medicines with a Outperform rating and announces Price Target of $90.

もっと見る
Mizuho Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $90